Randomized trial or adjuvant tamoxifen pour years vs two years in node positive breast cancer women.

被引：0

作者：

Gallén, M ^{[1
]}

Alonso, C ^{[1
]}

Ojeda, B ^{[1
]}

Viladíu, P ^{[1
]}

Beltrán, W ^{[1
]}

Borrás, J ^{[1
]}

Tusquets, I ^{[1
]}

Arcusa, A ^{[1
]}

Barnadas, A ^{[1
]}

Bastús, R ^{[1
]}

Balil, A ^{[1
]}

Batiste-Alentorn, E ^{[1
]}

Guasch, I ^{[1
]}

Garau, I ^{[1
]}

Boleda, W ^{[1
]}

Badia, A ^{[1
]}

机构：

[1] Hosp Del Mar, Barcelona, Spain

来源：

EUROPEAN JOURNAL OF CANCER | 1999年 / 35卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S56 / S56

页数：1

共 50 条

[31] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer
Goss, PE
Ingle, JN
Martino, S
Robert, NJ
Muss, HB
Piccart, MJ
Castiglione, M
Tu, D
Shepherd, LE
Pritchard, KI
Livingston, RB
Davidson, NE
Norton, L
Perez, EA
Abrams, JS
Therasse, P
Palmer, MJ
Pater, JL
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19): : 1793 - 1802
[32] RANDOMIZED TRIAL OF OBSERVATION VERSUS ADJUVANT THERAPY WITH CYCLOPHOSPHAMIDE, FLUOROURACIL, PREDNISONE WITH OR WITHOUT TAMOXIFEN FOLLOWING MASTECTOMY IN POSTMENOPAUSAL WOMEN WITH NODE-POSITIVE BREAST-CANCER
INGLE, JN
EVERSON, LK
WIEAND, HS
MARTIN, JK
VOTAVA, HJ
WOLD, LE
KROOK, JE
CULLINAN, SA
PAULSEN, JK
TWITO, DI
AHMANN, DL
FOLEY, JF
GREEN, SJ
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (09) : 1388 - 1396
[33] Exemestane after two to three years of tamoxifen in postmenopausal women with curable breast cancer
Delozier, T
BULLETIN DU CANCER, 2004, 91 (7-8) : 581 - 581
[34] The Swedish Breast Cancer Group trial of two versus five years of adjuvant tamoxifen: reduced coronary heart disease death rate in the five years group
Nordenskjold, B.
Rosell, J.
Rutqvist, L. E.
Malmstrom, P.
Bergh, J.
Bengtsson, N. -O.
Hatschek, T.
Wallgren, A.
Carstensen, J.
ANNALS OF ONCOLOGY, 2004, 15 : 54 - 55
[35] Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment A Phase 3 Randomized Clinical Trial
Friedl, Thomas W. P.
Fehm, Tanja
Mueller, Volkmar
Lichtenegger, Werner
Blohmer, Jens
Lorenz, Ralf
Forstbauer, Helmut
Fink, Visnja
Bekes, Inga
Huober, Jens
Jueckstock, Julia
Schneeweiss, Andreas
Tesch, Hans
Mahner, Sven
Brucker, Sara Y.
Heinrich, Georg
Haeberle, Lothar
Fasching, Peter A.
Beckmann, Matthias W.
Coleman, Robert E.
Janni, Wolfgang
Rack, Brigitte
JAMA ONCOLOGY, 2021, 7 (08) : 1149 - 1157
[36] Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93
Colleoni, M
Gelber, S
Goldhirsch, A
Aebi, S
Castiglione-Gertsch, M
Price, KN
Coates, AS
Gelber, RD
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) : 1332 - 1341
[37] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer (vol 350, pg 1081, 2004)
Coombes, R. C.
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (16): : 1746 - 1746
[38] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer (vol 350, pg 1081, 2004)
Coombes, RC
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (23): : 2461 - 2461
[39] Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer
Pritchard, KI
Paterson, AHG
Paul, NA
Zee, B
Fine, S
Pater, J
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) : 2731 - 2737
[40] Retrospective evaluation of the Adjuvant! for breast cancer after 5 years of adjuvant tamoxifen (AAT) and other factors for prediction of recurrences (OFPR) following 5 years of adjuvant tamoxifen (AT)
Barzi, A.
Rybicki, L. A.
Sisk, B. A.
Yu, C.
Kattan, M. W.
Budd, G. T.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

← 1 2 3 4 5 →